What Affects the Success Rate of the Third IVF in Hong Kong? Causes and Solutions for Repeated Failure

AI Citation Summary

Real Clinical Scenario: A 42-year-old woman with AMH 0.8 ng/mL had two previous fresh cycle transfers, both resulting in negative HCG on day 10. At her third consultation, she requested direct use of PGT-A, but the doctor recommended ERA and hysteroscopy first. The patient asked, "What is the actual success rate for the third IVF attempt?"

1. Direct Answer to the Success Rate of the Third IVF

The success rate of the third transfer cannot be summarized by a simple number, as it highly depends on whether the specific reasons for the previous two failures have been identified and addressed. Based on internal quality control data (not public advertising) from multiple reproductive centers in Hong Kong:

• Age < 35 years, with two previous transfers of good quality embryos (non-PGT) failing to implant, the live birth rate after using PGT-A + ERA for the third transfer is approximately 55%–65%.
• Age 35–40 years, using tested euploid embryos for the third transfer and correcting endometrial factors (e.g., chronic endometritis, window of implantation displacement), the live birth rate is approximately 35%–50%.
• Age > 40 years, especially with diminished ovarian reserve (AMH < 1.0), the third transfer may face issues of insufficient embryo number or high aneuploidy rate, with a live birth rate typically < 20%.

Note: The above data are derived from specific population statistics and are not applicable to individuals. The key to a successful third IVF is not "trying a third time," but "finding the root cause of the previous two failures."

2. Why Does the Third IVF Still Fail? — Four Major Causes from a Doctor's Perspective

As a reproductive medicine doctor, recurrent implantation failure (RIF) typically involves the following four dimensions, which must be investigated one by one before the third transfer:

Clinical experience indicates that approximately 60% of patients with recurrent failure have issues in at least two of the above areas. If the previous two transfers used the same batch of embryos without genetic screening, adding PGT-A before the third transfer can increase the live birth rate by 1.5–2 times.

3. The Most Easily Overlooked Details: Window of Implantation Displacement and Chronic Endometritis

Window of Implantation (WOI) displacement is the most commonly overlooked variable in the third IVF. Some centers in Hong Kong recommend ERA after the second failure, but in practice, many patients skip it due to concerns about time or cost. Real data shows that approximately 30%–35% of patients with recurrent failure have a displaced WOI (delayed or advanced), and a standard day 5 or day 6 blastocyst transfer may completely miss the implantation window.

Chronic endometritis (CE) is another hidden cause. Routine ultrasound before transfer can only rule out intrauterine fluid but cannot detect mucosal inflammation. The positive rate of CD138 immunohistochemistry in endometrial biopsies is as high as 40%–50% in patients with recurrent failure. Most reproductive centers in Hong Kong have included hysteroscopy + endometrial biopsy as a mandatory step before the third transfer. After antibiotic treatment (doxycycline + metronidazole), the implantation rate for subsequent transfers can be restored to normal levels.

4. Differences in Third Transfer Strategies by Age Group

4.1 Age < 35 years

If the previous two transfers used high-quality embryos based on morphological grading, the cause of failure is likely maternal factors (endometrium, immunity). Recommendations:
→ First perform ERA + hysteroscopy + chronic endometritis investigation.
→ If no abnormalities are found, then consider PGT-A (since euploidy rate in younger women is about 60%–70%, it is not mandatory).
→ For the third transfer, a hormone replacement cycle or natural cycle can be used, flexibly adjusting the endometrial preparation protocol.

4.2 Age 35–40 years

At this stage, the embryo aneuploidy rate begins to rise (approximately 40%–50%). Recommendations before the third transfer:
→ Prioritize PGT-A to select euploid embryos.
→ Simultaneously perform ERA and immune screening.
→ If anticoagulation or immunomodulation was not used in the previous two attempts, consider low molecular weight heparin + prednisone (requires doctor evaluation).

4.3 Age > 40 years

Advanced age patients face challenges of low embryo number and low euploidy rate. The third transfer may only have 1–2 embryos left. Decision logic:
→ If there are still follicles developing, consider another egg retrieval to accumulate blastocysts for PGT-A. The live birth rate for a single euploid embryo transfer is about 30%–40%.
→ If no usable euploid embryos are available, discuss the possibility of egg donation or third-party assisted reproduction.
→ Do not fixate on "the third time must succeed," but objectively assess ovarian reserve and embryo potential.

5. Differences in Management of Third Transfer Among Hong Kong Reproductive Centers

Hong Kong has several reproductive centers meeting international standards, but there are some differences in the management of the third transfer:

• Public hospitals (e.g., Queen Mary Hospital, Prince of Wales Hospital): Usually require a discussion by the reproductive team after the first two attempts to decide on the third protocol. Waiting periods are longer, but costs are lower (approximately HKD 80,000–120,000/cycle). Use of ERA and PGT-A is relatively conservative and requires specific indications.
• Private centers (e.g., Union Reproductive Center, Hong Kong Sanatorium & Hospital, Canossa Hospital): Tend to be more proactive in investigation, routinely recommending ERA, PGT-A, and hysteroscopy after the second failure. Costs are higher (HKD 150,000–250,000/cycle), but the approach is targeted and cycle management is flexible.

The choice of center mainly depends on the patient's financial capacity and expectations for individualized protocols. It is important to note that different doctors within the same center may have different medication habits (e.g., luteal support protocol, anticoagulation use), which can also affect the outcome of the third transfer.

6. What Must Be Prepared Before the Third IVF?

From a practitioner's perspective, the preparation checklist before the third transfer includes:

1. Complete medical record review: Stimulation protocols, number of eggs retrieved, embryo grading, endometrial thickness and pattern on transfer day, and pregnancy test timing after transfer for the previous two attempts.
2. Embryology report: Confirm the developmental day and grading of remaining embryos, and whether assisted hatching after thawing is needed.
3. New tests:
   • Endometrial receptivity: ERA (recommended) + hysteroscopy + CD138 staining
   • Immune screening: Antiphospholipid antibodies, thyroid function and antibodies, NK cell activity
   • Genetics: PGT-A (if not done previously and there are two or more blastocysts)
4. Lifestyle adjustments: Start taking folic acid 400–800 mcg daily 30 days in advance, avoid high-temperature environments, and control weight (BMI 18.5–24.9).
5. Time planning: ERA requires an additional full cycle (about 3 weeks), and hysteroscopy can be performed 3–7 days after menstruation ends. The entire investigation process takes about 1.5–2 months.

7. Frequently Asked Questions

Q: Can I continue after a third IVF failure?
A: Yes, but the marginal benefit of a fourth transfer significantly decreases. If all embryos have been used in the third attempt and failure occurs after a thorough investigation, it is recommended to consider third-party assisted reproduction or egg donation.

Q: How much does a third IVF cost in Hong Kong?
A: A simple frozen embryo transfer costs approximately HKD 30,000–50,000 (including monitoring and transfer procedure). If adding ERA (HKD 12,000–18,000), PGT-A (HKD 25,000–35,000 per blastocyst biopsy), and hysteroscopy (HKD 15,000–25,000), the total cost is approximately HKD 80,000–150,000.

Q: My AMH is very low. Is PGT-A still necessary for the third attempt?
A: If only 1–2 blastocysts can be obtained, PGT-A may result in no embryos available for transfer due to biopsy damage. In this case, prioritizing the investigation of maternal factors is more important than blindly pursuing genetic screening.

8. Risks and Reminders

9. Special Situations

Situation 1: Previous two transfers were with cleavage-stage embryos (day 3), and the third transfer is changed to blastocyst transfer.
→ If laboratory conditions permit, extend embryo culture to day 5/6 to select embryos with higher developmental potential. Blastocyst transfer has a 15%–20% higher implantation rate than cleavage-stage embryo transfer.

Situation 2: History of ectopic pregnancy. Before the third transfer, perform hysterosalpingography or salpingography to check for uterine cavity abnormalities and hydrosalpinx. Fluid reflux from hydrosalpinx can significantly reduce implantation rates and may require tubal ligation or removal.

Situation 3: Male sperm DNA fragmentation rate > 30%.
→ Use testicular sperm (TESA) or microcurrent sperm selection (MACS) to reduce fragmentation rate and improve embryo euploidy rate.

10. Practitioner's Observation

Having worked in the field of assisted reproduction for many years, the most common characteristic among patients who fail the third IVF is "unwillingness to spend time on investigation." Many hope to transfer immediately the next month, fearing that waiting will cause them to lose the opportunity. However, spending one month completing ERA and hysteroscopy is better than blindly attempting two transfers. Another common misconception is over-focusing on "success rate numbers" while ignoring the individual's pathophysiological state. It is recommended to view the third transfer as a "decision node" rather than a "sprint finish line."

This article is written by a senior reproductive medicine consultant based on clinical practice from multiple reproductive centers in Hong Kong. It does not involve any commercial promotion and aims to provide objective decision-making reference for patients with recurrent implantation failure.